Is amivantamab included in medical insurance?

Amivantamab is an innovative targeted drug that has just entered the Chinese market. Its trade name is Rybrevant. It has not been on the market for a long time, so the issue of medical insurance coverage has become a common focus for patients. At present, according to public information, the drug has not yet been included in the national medical insurance catalog, which also means that patients need to bear all costs when purchasing the drug. Since evantumumab is an imported innovative drug, mainly used for the treatment of non-small cell lung cancer, and the R&D investment and production costs are high, the current market price is still at a high level, which is undoubtedly a heavy burden for patients taking long-term medication.

Judging from the operating logic of medical insurance policies, the inclusion of innovative drugs usually requires several steps, including the accumulation of real-world efficacy and safety data after listing, price negotiations between pharmaceutical companies and the medical insurance bureau, and consideration of the overall affordability of the medical insurance fund. Evantumumab has been approved by FDA and other agencies overseas, and is supported by relevant clinical data. However, its time to market in the Chinese market is still short, and it still needs a certain period of time to complete the medical insurance access evaluation. Referring to the past path for innovative drugs to enter medical insurance, it generally takes several years to be included in the medical insurance catalog through substantial price reductions during price negotiations. Therefore, whether Carestream can enter medical insurance in the future depends on the pricing strategy of pharmaceutical companies and further verification of clinical value.

However, China's medical insurance system has become more positive in recent years towards innovative anti-cancer drugs. A number of imported targeted drugs have been significantly reduced in price through negotiation and included in the scope of medical insurance reimbursement, which has greatly improved patients' drug accessibility. If evantumumab can lower its price in future negotiations, the prospect of its entry into medical insurance can be expected. Prior to this, patients may reduce financial pressure through assistance projects, charitable funds or cross-border drug purchase channels, but they still need to ensure that the source of drugs is formal and legal to ensure safety and efficacy.

Reference materials:https://www.rybrevant.com/